Table 1 Neutralizing EV71 capsid-specific human monoclonal antibodies

From: Epitope-associated and specificity-focused features of EV71-neutralizing antibody repertoires from plasmablasts of infected children

mAb a

V H

D H

J H

Heavy-chain junction sequence

Mut b

λ/ƙ

V ƙ /V λ

J ƙ /J λ

Light-chain junction sequence

Mut b

Neut (µg  ml −1 ) c

Donor M

           

 Group 1

           

  16-2-11B

1-46*01 or 03

2-21*02

4*02

CARNYNGYCAGDCYSPDFW

23 (16)

λ

2-14*01

2*01 or 3*01 or 3*02

CSAFTTSSTLVF

18 (12)

0.78/0.39

  16-1-10B

1-46*01 or 03

2-21*02

4*02

CARNYNGYCAGECYSPDYW

23 (10)

λ

2-14*01

2*01 or 3*01 or 3*02

CSSFTTSSTLVF

20 (14)

0.89/0.45

 Group 2

           

  16-2-2D

1-46*01 or 02 or 03

3-22*01

6*02

CARGPGPGGKYYYDSSDAYYYYGMDVW

28 (18)

λ

1-44*01

1*01

CAAWDDRLNAYVF

13 (7)

0.50/2.01

 Group 3

           

  16-3-3C

3-9*01

6-19*01

6*02

CAKDGPSSGWSYQNYYNAMDVW

22 (14)

λ

2-11*01

2*01 or 3*01 or 3*02

CCSYAGSDTLVF

12 (8)

2.01/1.00

  16-3-5C

3-9*01

6-19*01

6*02

CAKDGPSSGWSYQNYYNAMDVW

18 (11)

λ

2-11*01

2*01 or 3*01 or 3*02

CCSYAGSDTLVF

9 (7)

1.25/2.50

 Group 4

           

  16-2-12D

4-39*01

2-2*01

4*02

CARHASPHCSSTSCYDGPYNKNWYVDLW

21 (15)

λ

1-47*02

2*01 or 3*01

CAAWDDSLSGLVF

13 (4)

1.55/1.55

 Group 5

           

  16-2-9D

4-39*01 or 02

2-2*01

4*02

CARHSSPQCSPTSCYEGPYTRDWYVDYW

24 (16)

λ

1-44*01

2*01 or 3*01

CAAWDGSLNAVVF

13 (8)

0.90/0.90

  16-2-6B

4-39*01 or 02

2-2*01

4*02

CARHSSPQCSPTSCYEGPYTRNWYVDYW

23 (17)

λ

1-44*01

2*01 or 3*01

CAAWDDSLNAVVF

8 (4)

3.22/0.81

 Group 6

           

  16-1-4A

4-39*01

6-19*01

6*02

CARHVPVAGFGYYYYGMDVW

19 (11)

λ

1-44*01

3*02

CAAWDDSLNNWVF

10 (8)

8.25/−

  16-1-7A

4-39*01

6-19*01

6*02

CARHVPVAGFGYYYYGMDVW

22 (12)

λ

1-44*01

3*02

CAAWDDSLNNWVF

11 (8)

6.60/−

  16-1-8A

4-39*01

6-19*01

6*02

CARHVPVAGFGYYYYGMDVW

23 (12)

λ

1-44*01

3*02

CAAWDDSLNNWVF

9 (7)

10.00/−

  16-1-3B

4-39*01

6-19*01

6*02

CARHVPVAGFGYYYYGMDVW

25 (13)

λ

1-44*01

3*02

CAAWDDSLNNWVF

9 (7)

7.15/−

  16-1-12B

4-39*01

6-19*01

6*02

CARHVPVAGFGYYYYGMDVW

24 (13)

λ

1-44*01

3*02

CAAWDDSLNNWVF

11 (8)

9.25/−

  16-2-10A

4-39*01

6-19*01

6*02

CARHVPVAGFGYYYYGMDVW

25 (14)

λ

1-44*01

3*02

CAAWDDSLNNWVF

10 (7)

9.55/−

  16-2-11D

4-39*01

6-19*01

6*02

CARHVPVAGFGYYYYGMDVW

23 (15)

λ

1-44*01

3*02

CAAWDDSLNTWVF

10 (7)

7.40/−

  16-3-10A

4-39*01

6-19*01

6*02

CARHVPVAGFGYYYYGMDVW

22 (13)

λ

1-44*01

3*02

CAAWDDSLNNWVF

12 (8)

7.60/−

  16-3-4D

4-39*01

6-19*01

6*02

CARHVPVAGFGYYYYGMDVW

21 (12)

λ

1-44*01

3*02

CAAWDDSLNNWVF

10 (7)

3.05/−

  16-3-8D

4-39*01

6-19*01

6*02

CARHVPVAGFGYYYYGMDVW

27 (15)

λ

1-44*01

3*02

CAAWDDSLNNWVF

10 (7)

7.75/−

 Group 7

           

  16-2-8C

4-39*03

2-2*01

4*02

CVRHSSPQCSPTSCYEGPYTRDWYVDYW

28 (16)

λ

1-44*01

2*01 or 3*01

CAAWDGSLNAVVF

13 (8)

0.09/0.09

 Group 8

           

  16-3-10B

7-4-1*02

1-14*01

5*02

CAYDPLGNWFDPW

21 (12)

λ

2-23*01 or 03

1*01

CCSYAGTRTYVF

16 (9)

0.03/0.03

Donor Y

           

 Group 1

           

  17-1-12A

3-11*05

1-26*01

6*02

CAREKWEKLGKLYYYGLDVW

30 (20)

ƙ

2-28*01 or 2D-28*01

2*02

CMQALQTPRTF

6 (4)

0.93/7.45

  17-3-5A

3-11*05

1-26*01

6*02

CAREKWEKLGKLYYYGLDVW

25 (18)

ƙ

2-28*01 or 2D-28*01

2*02

CMQALQTPRTF

7 (4)

0.95/7.60

 Group 2

           

  17-2-12A

3-23*04

3-16*01

6*02

CAKSVAARRFYFYYGMDAW

28 (18)

λ

7-43*01

3*02

CLLYYGGSQLWVF

14 (8)

10.25/−

  17-3-2A

3-23*04

3-16*01

6*02

CAKSVAARRFYFYYGMDAW

22 (17)

λ

7-43*01

3*02

CLLYYGGSQLWVF

13 (8)

11.10/−

  17-3-10A

3-23*04

3-16*01

6*02

CAKSVAARRFYFYYGMDAW

27 (16)

λ

7-43*01

3*02

CLLYYGGSQLWVF

12 (6)

13.40/−

  17-3-11D

3-23*04

3-16*01

6*02

CAKSVAARRFYFYYGMDAW

24 (16)

λ

7-43*01

3*02

CLLYYGGSQLWVF

9 (7)

11.15/−

 Group 3

           

  17-2-2B

4-39*01

3-10*01

4*02

CARTYGSGSYWGYFEYW

3 (3)

λ

2-8*01

3*02

CSSYAGSNNWVF

1 (0)

0.87/0.87

Donor Z

           

 Group 1

           

  34-1-6D

7-4-1*02

1-7*01

6*02

CARAKALLYYGMDVW

4 (3)

ƙ

1-39*01 or 1D-39*01

4*01

CQQSYSTPLTF

0 (0)

4.70/9.40

  34-2-3A

7-4-1*02

1-7*01

6*02

CARAKALLYYGLDVW

3 (2)

ƙ

1-39*01 or 1D-39*01

4*01

CQQSYSTPLTF

1 (0)

9.75/9.75

  34-2-5A

7-4-1*02

1-7*01

6*02

CARAKALLYYGMDVW

5 (3)

ƙ

1-39*01 or 1D-39*01

4*01

CQQSYSSPLTF

3 (1)

4.95/9.90

  34-2-9B

7-4-1*02

1-7*01

6*02

CARAKALLYYGMDVW

2 (1)

ƙ

1-39*01 or 1D-39*01

4*01

CQQSYSSPLTF

2 (1)

4.78/9.55

  34-2-1C

7-4-1*02

1-7*01

6*02

CARAKALLYYGLDVW

2 (2)

ƙ

1-39*01 or 1D-39*01

4*01

CQQSYSTPLTF

2 (0)

7.10/7.10

  34-2-5D

7-4-1*02

1-7*01

6*02

CARAKALLYYGMDVW

6 (3)

ƙ

1-39*01 or 1D-39*01

4*01

CQQSYSTPLTF

1 (0)

6.45/6.45

  34-3-4A

7-4-1*02

1-7*01

6*02

CARAKALLYYGMDVW

1 (1)

ƙ

1-39*01 or 1D-39*01

4*01

CQQSYSSPLTF

3 (1)

9.95/9.95

  34-3-4B

7-4-1*02

1-7*01

6*02

CARAKALLYYGLDVW

7 (4)

ƙ

1-39*01 or 1D-39*01

4*01

CQQSYSTPLTF

0 (0)

9.70/9.70

  34-3-6B

7-4-1*02

1-7*01

6*02

CARAKALLYYGLDVW

5 (4)

ƙ

1-39*01 or 1D-39*01

4*01

CQQSYSTPLTF

0 (0)

9.65/9.65

  34-3-1C

7-4-1*02

1-7*01

6*02

CARAKALLYYGMDVW

4 (3)

ƙ

1-39*01 or 1D-39*01

4*01

CQQSYSTPLTF

1 (0)

8.10/16.20

  34-3-8D

7-4-1*02

1-7*01

6*02

CARAKALLYYGMDVW

1 (1)

ƙ

1-39*01 or 1D-39*01

4*01

CQQSYSTPLTF

2 (1)

7.65/7.65

  1. DH, diversity gene segment of the heavy-chain variable domain; JH, joining gene segment of the heavy-chain variable domain; Mut, mutation number; J λ joining gene segment of the lambda light-chain variable domain; Neut, neutralization; VH, variable gene segment of the heavy-chain variable domain; Vƙ, variable gene segment of the kappa light-chain variable domain; Vλ, variable gene segment of the lambda light-chain variable domain; Jƙ joining gene segment of the kappa light-chain variable domain
  2. aRepresentative neutralizing monoclonal antibodies (mAb) from each of the 12 variable domain-related groups are shown in bold
  3. bThe number of nucleotide mutations in the heavy- and light-chain variable domains and the number of amino acid replacements (shown in parentheses). The variable domain consists of the framework regions (FR1, FR2, FR3, and FR4) and complementarity determining regions (CDR1, CDR2, and CDR3). To determine the individual gene segments employed by VDJ and VJ rearrangements and the number of nucleotide mutations and amino acid replacements, the variable domain sequences were aligned with germline gene segments using the international ImMunoGeneTics (IMGT) alignment tool
  4. cThe lowest concentration of the mAb-containing supernatant that showed 100% inhibition of EV71 12-96015 (B5)/11-96023 (C4)-induced CPE. -: no neutralization
Back to article page